Dr. Kuifeng Wang has multiple years of experience in structural biology research, clinical research and corporate management. He is specialized in novel target and MoA validation, drug discovery and clinical development. Dr. Wang founded Genhouse Bio in 2014 and successfully transformed Genhouse Bio into a new drug development company in 2017. He is responsible of drug discovery and clinical development in Genhouse.

Dr. Wang is honored with National Leading Expert of Drug Discovery and Innovative and Entrepreneurial Talent of Jiangsu Province. He received a M.D. from Anhui Medical University in clinical medicine and holds a Ph.D. from Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

Dr. Mike Liu is responsible for business development and corporate strategy of Genhouse and has a wealth of experience in business and corporate development.

Dr. Liu held leadership positions within the global business development team of both Alphamab and Jiangsu Hengrui, where he successfully led multiple deals between MNC and China domestic biotech companies. Before that, Dr. Liu also worked for Alexion Pharmaceuticals and Purdue Pharma in global business development and licensing.

Dr. Liu received a B.S. from Nanjing University in Biochemistry and holds a Ph.D. in Cancer Biology from Eppley Cancer Institute and an MBA from Washington University.

Dr. Jie Jack Li is responsible for global drug discovery of Genhouse. Dr. Jie Jack Li has had over 25 years of experience in medicinal chemistry and drug discovery in both big pharma and biotechnology companies in the US including Pfizer, BMS, and Revolution Medicines. . In addition, Dr. Li took a four-year sojourn as an associate professor at the University of San Francisco. Before joining GenHouse, Dr. was a vice president of Discovery Chemistry at ChemPartner. Dr. Li has written extensively in the fields of organic chemistry, medicinal chemistry, and history of drug discovery. In addition to 34 research articles and 12 patents, he has published over 30 books on organic chemistry, medicinal chemistry, and history of drug discovery.

In terms of education, Dr. Li earned his B.S. and M.S. degrees in polymer chemistry at Nanjing University in 1983 and 1987, respectively. After having earned his Ph.D. in Organic Chemistry from Indiana University in 1995, he carried out his postdoctoral research at Massachusetts Institute of Technology.

Dr. Kuifeng Wang has multiple years of experience in structural biology research, clinical research and corporate management. He is specialized in novel target and MoA validation, drug discovery and clinical development. Dr. Wang founded Genhouse Bio in 2014 and successfully transformed Genhouse Bio into a new drug development company in 2017. He is responsible of drug discovery and clinical development in Genhouse.

Dr. Wang is honored with National Leading Expert of Drug Discovery and Innovative and Entrepreneurial Talent of Jiangsu Province. He received a M.D. from Anhui Medical University in clinical medicine and holds a Ph.D. from Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

Dr. Mike Liu is responsible for business development and corporate strategy of Genhouse and has a wealth of experience in business and corporate development.

Dr. Liu held leadership positions within the global business development team of both Alphamab and Jiangsu Hengrui, where he successfully led multiple deals between MNC and China domestic biotech companies. Before that, Dr. Liu also worked for Alexion Pharmaceuticals and Purdue Pharma in global business development and licensing.

Dr. Liu received a B.S. from Nanjing University in Biochemistry and holds a Ph.D. in Cancer Biology from Eppley Cancer Institute and an MBA from Washington University.

Dr. Jie Jack Li is responsible for global drug discovery of Genhouse. Dr. Jie Jack Li has had over 25 years of experience in medicinal chemistry and drug discovery in both big pharma and biotechnology companies in the US including Pfizer, BMS, and Revolution Medicines. . In addition, Dr. Li took a four-year sojourn as an associate professor at the University of San Francisco. Before joining GenHouse, Dr. was a vice president of Discovery Chemistry at ChemPartner. Dr. Li has written extensively in the fields of organic chemistry, medicinal chemistry, and history of drug discovery. In addition to 34 research articles and 12 patents, he has published over 30 books on organic chemistry, medicinal chemistry, and history of drug discovery.

In terms of education, Dr. Li earned his B.S. and M.S. degrees in polymer chemistry at Nanjing University in 1983 and 1987, respectively. After having earned his Ph.D. in Organic Chemistry from Indiana University in 1995, he carried out his postdoctoral research at Massachusetts Institute of Technology.

Dr. Haidan Wang is responsible for global clinical development of Genhouse. Prior to joining Genhouse, Dr. Wang was the Vice President of Clinical Development at CSPC Pharmaceutical Group. Before that, he had served in multiple positions in the clinical development function of several well-known CRO or pharma such as Novartis, R&G Pharma, Salubris and JW Therapeutics. In his twelve-year experience in clinical development, Dr. Wang has successfully led five programs to NDA/BLA submission and approval. 

Before entering the pharmaceutical industry, Dr. Wang worked in the oncology department of a tier-one hospital for six years and had rich experience of clinical diagnosis and treatment. He also worked at Beijing Drug Administration and has a deep understanding of drug regulation in China. Dr. Wang received a doctorate of medicine (M.D.) degree from Air Force Medical University (The Fourth Military Medical University).

Dr. Guiping Zhang is in charge of drug design and development in Genhouse.

Dr. Zhang worked for both domestic and global pharma for many years. He brings profound understanding of drug discovery and CMC process development to Genhouse. He also had extensive experience in drug discovery project and team management.

Dr. Zhang is honored with Global High-level Talent in biomedical field of Shenzhen. He also serves as a professional reviewer for Bioorganic & Medicinal Chemistry Letters and Science Journal of Chemistry. He received a B.S. from Huazhong University of Science and Technology and a Ph.D. from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He did post-doctoral research at the University of Illinois at Chicago.

Jasper Li is in charge of preclinical development and evaluation of drug candidates in Genhouse.

He is an experienced drug hunter with multiple-year experience of small molecule drug discovery, drug development and early-stage clinical operation. He has led the development of a dozen innovative drug candidates, five of those have already entered clinical development in China or the U.S.

He gained a B.S. from Nanjing University in Biochemistry and a M.S. from Shanghai Institute of Materia Medica, Chinese Academy of Sciences in Pharmacology.